Medical Professionals

Developing Novel Immunotherapy Treatments

Atara Biotherapeutics is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Our commitment is to make every effort to support patients in need of treatment options.

Our Clinical Studies

Our clinical studies evaluate the potential of our investigational treatments in a well-defined patient population with eligibility criteria that allow for appropriate assessment of safety and clinical effect. If you are interested in learning more about our ongoing clinical studies, please contact us at

Expanded Access Programs

We also recognize our clinical studies will not be available to all patients who have life threatening diseases and no satisfactory treatment alternatives. For these patients, we have expanded access programs for Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD) and other EBV associated hematologic and solid tumors. Click here to learn more about these programs.

There may also be instances where there is a significant patient need that we have not anticipated or encountered. If you would like to discuss availability of investigational drug product for a specific patient in significant need, or if you have a specific research idea, please contact us at

Clinical Studies

Clinical Studies Aimed at Addressing Unmet Medical Needs

There is a high unmet medical need for additional effective immunotherapies. We believe our novel treatments currently in clinical development have the potential to change the way we approach certain life-threatening diseases.

Clinical Studies Aimed at Addressing Unmet Medical Needs

Requests for Expanded Access

This Policy for Requests for Expanded Access to Investigational Drugs describes the principles and procedures that Atara Biotherapeutics will follow when considering requests by licensed physicians for use of Atara’s investigational drugs outside of clinical trials.
View Policy